AI Verdict
KOSS has stronger fundamentals based on our AI analysis.
KPHMW vs KOSS Fundamental Comparison
| Metric | KPHMW | KOSS |
|---|---|---|
| Revenue | $0.0 | $6.9M |
| Net Income | $-10.8M | $-321,678.0 |
| Net Margin | N/A | -4.6% |
| ROE | -67.2% | -1.1% |
| ROA | -44.7% | -0.9% |
| Current Ratio | 5.99x | 12.84x |
| Debt/Equity | 0.02x | 0.00x |
| EPS | $-2.64 | $-0.03 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
KPHMW vs KOSS: Frequently Asked Questions
Is KPHMW or KOSS a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), KOSS has stronger fundamentals. KPHMW is rated STRONG SELL (78% confidence) while KOSS is rated SELL (78% confidence). This is not investment advice.
How does KPHMW compare to KOSS fundamentally?
KIORA PHARMACEUTICALS INC has ROE of -67.2% vs KOSS CORP's -1.1%. Net margins are N/A vs -4.6% respectively.
Which stock pays higher dividends, KPHMW or KOSS?
KPHMW has a dividend yield of N/A or no dividend while KOSS has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in KPHMW or KOSS for long term?
For long-term investing, consider that KPHMW has STRONG SELL rating with 78% confidence, while KOSS has SELL rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about KPHMW vs KOSS?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For KPHMW vs KOSS, the AI consensus favors KOSS based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.